Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease

Journal of Neural Transmission

Volumn 103, Issue 4, 1996, Pages 421-432

  Moser, A ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

5 hydroxyindole acetic acid; Dopamine metabolites; Hallucinations; Parkinson's disease; Salsolinol

Indexed keywords

3 O METHYLDOPA; 5 HYDROXYINDOLEACETIC ACID; HOMOVANILLIC ACID; LEVODOPA; SALSOLINOL; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CATECHOLAMINE METABOLISM; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; ELECTROCHEMICAL DETECTION; FEMALE; HALLUCINOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEROTONINERGIC SYSTEM; URINE LEVEL; VISUAL HALLUCINATION;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BIOLOGICAL MARKERS; CATECHOLAMINES; FEMALE; HALLUCINATIONS; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; ISOQUINOLINES; LEVODOPA; MALE; PARKINSON DISEASE; REFERENCE VALUES; REGRESSION ANALYSIS; TYROSINE;

EID: 0029972510     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01276418     Document Type: Article

References (26)

1. Airaksinen MM, Saano V, Steidel E, Juvonen H, Huhtikangas A, Gynther J (1984) Binding of β-carbolines and tetrahydroisoquinolines by opiate receptors of the o-type. Acta Pharmacol Toxicol 55: 380-385
2. Banerjee AK, Falkai PG, Savidge M (1989) Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J 65: 358-361
3. Celada P, Artigas F (1993) Plasma 5-hydroxyindole acetic acid as an indicator of monoamine oxidase A inhibition in rat brain and peripheral tissues. J Neurochem 61: 2191-2198
4. Cheng AVT, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, Edwardson JA, Perry RH, Perry EK (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 106: 50-55
5. Collins MA, Nijm WP, Borge GF, Teas G, Goldfarb C (1979) Dopamine related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption. Science 206: 1184-1186
6. Cummings JL (1992) Psychosis in neurologic disease: neurobiology and pathogenesis. Neuropsychiatr Neuropsychol Behav Neurol 5: 144-150
7. Damasio AR, Antunes JL, Macedo C (1971) Psychiatric aspects in parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry 34: 502-507
8. Dostert P, Strolin Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases. J Neural Transm 74: 61-74
9. Dostert P, Strolin Benedetti M, Dordain G, Vernay D (1989) Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar. J Neural Transm [P-D Sect] 1: 269-78
10. Dostert P, Strolin Benedetti M, Bellotti V, Allievi C, Dordain G (1990) Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects. J Neural Transm [Gen Sect] 81: 215-223
11. 18 cartridges followed by high performance liquid chromatographic analysis with electrochemical detection. J Chromatogr 380: 379-385
12. Gjerris A, Werdelin L, Rafaelsen O, Alling C, Christensen NJ (1987) CSF dopamine increased in depression: CSF dopamine, noradrenaline and their metabolites in depressed patients and in controls. J Affect Disord 13: 279-286
13. Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505-251
14. Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drup therapy. Am J Psychiatry 139: 494-497
15. Hartikainen P, Reinikainen KJ, Soininen H, Sirviö J, Soikkeli R, Riekkinen (1992) Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm [PD-Sect] 4: 53-68
16. Kaakkula S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbodopa on extracellular dopamine in the rat striatum. J Neurochem 60: 137-144
17. Klawans HL (1988) Psychiatric side effects during the treatment of Parkinson's disease. J Neural Transm [Suppl] 27: 117-122
18. Lauterbach EC (1993) Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry 150: 1750
19. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M (1992) Markers of dopamine metabolism in Parkinson's disease. Neurology 42: 2111-2117
20. Mahalanobis PC (1936) On the generalized distance in statistics. Proc Natl Inst Sci India 12: 49-55
21. Maruyama W, Nakahara D, Dostert P, Takahashi A, Naoi M (1993) Naturally-occuring isoquinolines perturb monoamine metabolism in the brain: studied by in vivo microdialysis. J Neural Transm [Gen Sect] 94: 91-102
22. Meco G, Bonifati V, Cusimano G, Fabrizio E, Vanacore N (1990) Hallucinations in Parkinson's disease: neuropsychological study. Ital J Neurol Sci 11: 373-379
23. Meco G, Alessandria A, Bonivati V, Giustini P (1994) Risperidone for hallucinations in levdopa-treated Parkinson's disease patients. Lancet 343: 1370-1371
24. Melamed E, Hefti F (1984) Mechanism of action of short- and long-term L-dopa treatment. Adv Neurol 40: 149-170
25. Minami M, Takahashi T, Maruyama W, Takahashi A, Dostert P, Nagatsu T, Naoi M (1992) Inhibition of tyrosine hydroxylase by R and S enantiomers of salsolinol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydro-isoquinoline. J Neurochem 58: 2097-2101
26. Minami M, Maruyama W, Dostert P, Nagatsu T, Naoi M (1993) Inhibition of type A and B monoamine oxidase by 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines and their N-methylated derivatives. J Neural Transm [Gen Sect] 92: 125-135